Lack of impact of early antibiotic therapy for streptococcal pharyngitis on recurrence rates
Related Experiment Videos
M A Gerber1, M F Randolph, K K DeMeo
1Department of Pediatrics, University of Connecticut School of Medicine, Farmington 06032.
Insights
Delaying antibiotic treatment for group A beta-hemolytic streptococcal (GABHS) pharyngitis by 48 hours does not affect recurrence rates. This study found similar rates of GABHS recurrence in both immediate and delayed treatment groups.
Area of Science:
- Infectious Diseases
- Microbiology
- Pediatrics
Background:
- Group A beta-hemolytic streptococcal (GABHS) pharyngitis is a common bacterial infection.
- The optimal timing for initiating antibiotic therapy to prevent recurrence is not fully established.
Purpose of the Study:
- To investigate if delaying antibiotic treatment for GABHS pharyngitis impacts recurrence rates.
- To compare homologous serotype recurrence between immediate and delayed penicillin V therapy groups.
Main Methods:
- A randomized controlled trial involving 113 patients diagnosed with GABHS pharyngitis.
- Patients were assigned to either immediate penicillin V treatment or a 48-hour delayed regimen.
- Follow-up throat cultures and serotyping were conducted at multiple time points post-treatment.
Main Results:
- No significant difference in recurrence rates was observed between the immediate-treatment group (12%) and the delayed-treatment group (14%).
- Patient demographics, illness duration, and clinical presentation were similar across both groups.
- Serotyping confirmed that the timing of treatment did not influence the rate of homologous GABHS recurrences.
Conclusions:
- A 48-hour delay in initiating penicillin V therapy for GABHS pharyngitis does not alter the rate of infection recurrence.
- Current treatment guidelines for GABHS pharyngitis may not require immediate antibiotic administration to prevent recurrence.
Abstract:
To determine whether recurrence rates for group A beta-hemolytic streptococcal (GABHS) pharyngitis are related to the time of initiation of antibiotic therapy, we randomly assigned 113 patients with GABHS pharyngitis either to a group that began a 10-day course of penicillin V at the time of diagnosis or to a group that began the same antibiotic regimen after a dealy of 48 hours. Follow-up throat culture specimens were obtained 4 days, 2 months, and 4 months after the completion of antibiotic therapy, as well as during any interim episodes of acute pharyngitis. Serotyping of all GABHS isolates was performed to distinguish between recurrences with homologous serotypes and new acquisitions with heterologous serotypes. There was no significant difference between the two treatment groups in age, gender, duration of illness before enrollment in the study, initial clinical presentation, or compliance. Of the 50 patients in the immediate-treatment group, 6 (12%) had homologous serotypes of GABHS isolated on one of the follow-up throat cultures. Of the 63 patients in the delayed-treatment group, 9 (14%) had homologous serotypes of GABHS isolated on one of the follow-up throat cultures. These data indicate that a 48-hour delay in the initiation of penicillin therapy for GABHS pharyngitis does not reduce the recurrence rate.